Congenital Sialidosis Type II (Hydropic/Congenital Severe Sialidosis): Comprehensive Disease Characteristics Report

Executive summary

Congenital sialidosis type II is the most severe prenatal-onset end of the NEU1-related lysosomal storage disorder spectrum (“sialidosis”), typically presenting in utero or at birth with nonimmune hydrops fetalis, ascites, and generalized edema and often resulting in stillbirth or death shortly after birth. It is caused by biallelic loss-of-function variants in NEU1 (autosomal recessive inheritance) leading to near-complete deficiency of lysosomal neuraminidase-1 (sialidase) activity and subsequent lysosomal accumulation and urinary excretion of sialylated oligosaccharides and glycopeptides (“sialyl-oligosacchariduria”). Recent 2023–2024 studies emphasize additional downstream mechanisms beyond “storage,” including dysregulated lysosomal exocytosis (via LAMP1 hypersialylation) and organ-specific consequences such as kidney disease (“nephrosialidosis”) linked to hypersialylation-dependent megalin trafficking defects. (khan2018sialidosisareview pages 3-5, vlekkert2024aavmediatedgenetherapy pages 1-5, kho2023severekidneydysfunction pages 1-2)

1. Disease information

1.1 Definition and overview

Sialidosis (mucolipidosis I) is an ultra-rare, autosomal recessive lysosomal storage disease caused by deficiency of lysosomal neuraminidase-1 (NEU1), leading to accumulation and excretion of sialylated metabolites. Clinical severity ranges from type I (attenuated) to type II (severe neuropathic). Type II is further subdivided into congenital/hydropic, infantile, and juvenile forms based on age at onset. (khan2018sialidosisareview pages 3-5, vlekkert2024aavmediatedgenetherapy pages 1-5, khan2018sialidosisareview pages 1-3)

The congenital/hydropic subtype is described as the severe prenatal form: “It manifests itself prenatally and is characterized by ascites and hydrops fetalis, hepatomegaly and stillbirths or death at a very early age.” (khan2018sialidosisareview pages 3-5)

1.2 Key identifiers

Table: This table summarizes the main identifiers and naming conventions for congenital sialidosis type II, linking the congenital/hydropic form to the broader type II disease entity. It is useful for harmonizing OMIM, MONDO, Orphanet, and coding terminology in a disease knowledge base.

Notes: In the retrieved evidence, identifiers are most consistently available at the disease-entity level (sialidosis; sialidosis type II) rather than as a separate MONDO/Orphanet entity specifically for the “congenital/hydropic” subtype. (OpenTargets Search: Sialidosis, khan2018sialidosisareview pages 3-5)

1.3 Synonyms and alternative names

Commonly used: - Sialidosis type II, congenital/hydropic subtype (or “congenital sialidosis”) (khan2018sialidosisareview pages 3-5, vlekkert2024aavmediatedgenetherapy pages 1-5) - Mucolipidosis I / sialidosis (vlekkert2024aavmediatedgenetherapy pages 1-5)

1.4 Source type of disease information

The congenital/hydropic phenotype is primarily derived from aggregated disease-level resources (reviews) that compile individual case reports and fetal pathology series (e.g., tabulated congenital cases). (khan2018sialidosisareview pages 3-5, khan2018sialidosisareview media 784849f6, khan2018sialidosisareview media 429fda1b, khan2018sialidosisareview media 29bee092)

2. Etiology

2.1 Disease causal factors

Genetic cause: biallelic pathogenic variants in NEU1 encoding lysosomal neuraminidase-1 (sialidase). (khan2018sialidosisareview pages 1-3, peng2025geneticinsightsand pages 1-2)

Primary mechanistic defect: deficient NEU1 activity prevents normal lysosomal catabolism of sialylated glycoconjugates, leading to lysosomal accumulation and abnormal excretion of sialylated oligosaccharides/glycopeptides. (vlekkert2024aavmediatedgenetherapy pages 1-5, mosca2020conventionalandunconventional pages 1-3, kho2023severekidneydysfunction pages 1-2)

2.2 Risk factors

• Family history / parental carrier status for autosomal recessive NEU1 variants. (khan2018sialidosisareview pages 11-13)
• Consanguinity and population founder variants are plausible contributors in ultra-rare AR diseases, but explicit consanguinity/founder-effect quantification for congenital type II was not available in retrieved primary sources.

2.3 Protective factors

No validated genetic or environmental protective factors specific to congenital sialidosis type II were identified in retrieved sources.

2.4 Gene–environment interactions

No established gene–environment interactions specific to congenital sialidosis type II were found in the retrieved evidence.

3. Phenotypes

3.1 Phenotype spectrum and HPO mapping

The congenital/hydropic subtype is characterized by prenatal fluid overload and early lethality; additional findings vary across cases. In a comprehensive review, the distinguishing congenital group features were “hydrops, ascites, and edema … followed by coarse features, dysostosis multiplex, and hepatosplenomegaly.” (khan2018sialidosisareview pages 3-5)

Table: This table maps the major prenatal, neonatal, and infantile manifestations of congenital/severe sialidosis type II to suggested Human Phenotype Ontology terms. It is designed for knowledge-base curation and highlights which findings are characteristic of the hydropic congenital form versus the broader severe type II spectrum.

3.2 Age of onset, progression, and severity

• Congenital/hydropic: prenatal onset; frequently lethal in utero or shortly after birth due to near-complete NEU1 deficiency. (khan2018sialidosisareview pages 3-5)
• Infantile/juvenile type II: early-life onset with multisystem disease including coarse facies, skeletal dysplasia/dysostosis multiplex, hepatosplenomegaly, neurodevelopmental impairment, and (in some) renal disease. (vlekkert2024aavmediatedgenetherapy pages 1-5, mosca2020conventionalandunconventional pages 1-3)

3.3 Frequency among affected individuals

Formal phenotype frequencies specifically for congenital/hydropic type II were not quantified in the retrieved evidence set. The congenital-case table compiled in the 2018 review provides case-by-case features rather than aggregate percentages. (khan2018sialidosisareview media 784849f6, khan2018sialidosisareview media 429fda1b, khan2018sialidosisareview media 29bee092)

3.4 Quality-of-life impact

For congenital/hydropic cases, quality-of-life measures are generally not applicable due to fetal/neonatal lethality. For infantile/juvenile type II survivors, major impacts include severe neurologic disability and multisystem complications; standardized HRQoL instruments (e.g., EQ-5D/SF-36) were not identified in retrieved sources.

4. Genetic / molecular information

4.1 Causal gene(s)

• NEU1 (neuraminidase 1), lysosomal sialidase. (peng2025geneticinsightsand pages 1-2)

NEU1 catalyzes lysosomal removal of terminal sialic acids; a recent genetics review states NEU1 “catalyzes the breakdown of sialic acid-containing substances within lysosomes by hydrolyzing terminal sialic acid residues.” (peng2025geneticinsightsand pages 1-2)

4.2 Inheritance

• Autosomal recessive (biallelic NEU1 variants). (khan2018sialidosisareview pages 1-3, peng2025geneticinsightsand pages 1-2)

4.3 Variant spectrum and genotype–phenotype

• A 2018 review reported “more than 40 mutations within the NEU1 gene” known at that time and emphasized genotype–phenotype correlation with residual neuraminidase activity. (khan2018sialidosisareview pages 3-5, khan2018sialidosisareview pages 1-3)
• A 2025 genetics review reported “Over 90 pathogenic NEU1 variants, predominantly missense mutations,” and another section noted ClinVar listing 94 probable pathogenic NEU1 variants. (peng2025geneticinsightsand pages 1-2, peng2025geneticinsightsand pages 4-6)
• Frameshift variants were described as “predominantly linked to type II” in the 2025 review, consistent with more severe loss-of-function. (peng2025geneticinsightsand pages 4-6)

Example genotype–phenotype detail (recent review): A reported patient with compound heterozygosity (exon3:c.544A>G and exon5:c.1021+1G>A) had neuraminidase activity “reduced to 6.4% of normal,” illustrating residual activity as a severity correlate. (peng2025geneticinsightsand pages 4-6)

4.4 NEU1 multienzyme complex and related disorders

NEU1 depends on a lysosomal multienzyme complex including PPCA/CTSA (protective protein/cathepsin A) and β-galactosidase (GLB1). In a 2024 preclinical gene-therapy study: “In mammalian tissues NEU1 is found in a high molecular weight complex with … PPCA … and … β-galactosidase” and “Interaction with PPCA is a prerequisite for the proper localization, stability and activation of NEU1. In absence of a functional PPCA, NEU1 is enzymatically silent.” (vlekkert2024aavmediatedgenetherapy pages 1-5)

This is central to the differential diagnosis with galactosialidosis (CTSA/PPCA deficiency) causing secondary NEU1 deficiency. (khan2018sialidosisareview pages 1-3, mosca2020conventionalandunconventional pages 1-3)

4.5 Epigenetics / chromosomal abnormalities

No disease-specific epigenetic alterations or recurrent chromosomal abnormalities were identified in the retrieved evidence.

5. Environmental information

Congenital sialidosis type II is a monogenic lysosomal disorder; no consistent environmental/lifestyle/infectious contributors were identified in retrieved sources.

6. Mechanism / pathophysiology

6.1 Core causal chain (current understanding)

NEU1 loss-of-function → lysosomal failure to desialylate glycoconjugates → storage of sialylated glycoproteins/oligosaccharides and systemic dysfunction. (vlekkert2024aavmediatedgenetherapy pages 1-5, mosca2020conventionalandunconventional pages 1-3)

A 2024 preprint abstract describes the foundational mechanism: “Sialidosis is a glycoprotein storage disease caused by deficiency of the lysosomal sialidase NEU1, which leads to pathogenic accumulation of sialylated glycoproteins and oligosaccharides in tissues and body fluids.” (vlekkert2024aavmediatedgenetherapy pages 1-5)

6.2 Dysregulated lysosomal exocytosis (LAMP1 axis)

Beyond storage, NEU1 has been characterized as a negative regulator of lysosomal exocytosis. In Neu1−/− mice, NEU1 deficiency increases LAMP1+ lysosomes docked at the plasma membrane, promoting extracellular release of lysosomal contents, with downstream tissue remodeling and fibrosis. (vlekkert2024aavmediatedgenetherapy pages 1-5, khan2018sialidosisareview pages 1-3)

6.3 Kidney involvement (nephrosialidosis) and megalin trafficking

A 2023 JCI Insight study focused on the severe renal presentation in a subset of type II patients (“nephrosialidosis”) and modeled it in Neu1-deficient mice. Its abstract states that mice exhibited “elevated urinary albumin levels, loss of nephrons, renal fibrosis, presence of storage vacuoles,” and that glycoprotein sialylation was increased, including megalin; “Megalin levels were severely reduced, and the protein was directed to lysosomes instead of the apical membrane,” supporting impaired proximal tubular protein reabsorption as a mechanism for proteinuria. (kho2023severekidneydysfunction pages 1-2)

6.4 Suggested pathway/ontology annotations

GO Biological Process (suggested): - Lysosomal catabolic process; glycoprotein catabolic process; lysosomal exocytosis; protein glycosylation/desialylation; endocytosis and receptor-mediated endocytosis; extracellular matrix organization/fibrosis; autophagy (renal findings include autophagy markers in mechanistic work). (vlekkert2024aavmediatedgenetherapy pages 1-5, kho2023severekidneydysfunction pages 9-11, kho2023severekidneydysfunction pages 1-2)

GO Cellular Component (suggested): - Lysosome; plasma membrane; endosome; extracellular space (lysosomal content release); glomerulus-related compartments (renal). (vlekkert2024aavmediatedgenetherapy pages 1-5, kho2023severekidneydysfunction pages 1-2)

Cell Ontology terms (suggested key cell types): - Kidney proximal tubule epithelial cell; podocyte; glomerular endothelial cell; macrophage/microglia (neuroinflammation/microgliosis in models); connective tissue fibroblast/myocyte (fibrosis/atrophy models). (khan2018sialidosisareview pages 5-7, kho2023severekidneydysfunction pages 9-11, vlekkert2024aavmediatedgenetherapy pages 1-5)

7. Anatomical structures affected

Organ-level involvement (severe type II spectrum): - Fetal/placental and systemic prenatal involvement with multiorgan vacuolation in congenital cases (liver, bone marrow, kidney, brain) and placental vacuolation indicating early fetal storage. (khan2018sialidosisareview pages 3-5, khan2018sialidosisareview pages 5-7) - Liver/spleen: hepatomegaly/hepatosplenomegaly. (khan2018sialidosisareview pages 3-5, vlekkert2024aavmediatedgenetherapy pages 1-5) - Skeletal system: dysostosis multiplex/skeletal dysplasia and vertebral deformities. (vlekkert2024aavmediatedgenetherapy pages 1-5, mosca2020conventionalandunconventional pages 1-3) - Central nervous system: severe neuropathology in type II; neurodegeneration mechanisms described in mouse models. (kho2023severekidneydysfunction pages 1-2, vlekkert2024aavmediatedgenetherapy pages 1-5) - Kidney: nephrosialidosis with glomerular nephropathy/nephrotic syndrome subset; megalin-mediated reabsorption defects in models. (kho2023severekidneydysfunction pages 1-2)

Subcellular localization: Lysosome (primary); plasma membrane docking/fusion events are emphasized in lysosomal exocytosis model; cell-surface hypersialylation affects trafficking receptors such as megalin. (vlekkert2024aavmediatedgenetherapy pages 1-5, kho2023severekidneydysfunction pages 1-2)

UBERON suggestions (high-level): fetal placenta, liver, spleen, kidney glomerulus, bone, brain.

8. Temporal development

• Onset: congenital/hydropic type II begins prenatally; infantile severe type II begins 0–12 months; juvenile 2–20 years (classification). (khan2018sialidosisareview pages 3-5, vlekkert2024aavmediatedgenetherapy pages 1-5)
• Progression: congenital cases are often lethal; Neu1−/− mice show neonatal onset and rapid progression with premature death (4–6 months in a commonly used model), supporting a rapidly progressive systemic-neurodegenerative course. (vlekkert2024aavmediatedgenetherapy pages 1-5)

9. Inheritance and population

9.1 Epidemiology

• A 2020 review reported sialidosis incidence estimates of “1:250,000 to 1:2,000,000 live births.” (mosca2020conventionalandunconventional pages 1-3)
• A 2023 mechanistic paper stated prevalence “less than 1/1,000,000 live births.” (kho2023severekidneydysfunction pages 1-2)

These values are for sialidosis overall; congenital/hydropic type II is expected to be rarer, but subtype-specific rates were not found in retrieved sources.

9.2 Population/variant distribution and phenotype statistics

A 2025 genetics review summarized population differences across sialidosis cohorts (not limited to congenital type II): - “Asian patients exhibit a lower incidence of impaired cognition (21.7%) … [vs] Caucasian patients (50.0%)” and “the occurrence of cherry-red patches is also lower in Asians (40.7% compared to 61.1% in Caucasians, P = 0.02).” (peng2025geneticinsightsand pages 2-4, peng2025geneticinsightsand pages 4-6)

A Taiwan-associated variant (c.544A>G; p.Ser182Gly) was highlighted as common in Asians and absent in Caucasians in the same review. (peng2025geneticinsightsand pages 4-6)

9.3 Penetrance/expressivity

Congenital type II is associated with profound loss of enzyme function and high severity; explicit penetrance estimates were not identified.

10. Diagnostics

Table: This table summarizes the core diagnostic workflow and major differential-diagnostic issues for congenital sialidosis type II. It highlights the complementary roles of urine oligosaccharide screening, fibroblast neuraminidase assays, beta-galactosidase testing, and molecular confirmation, including key pitfalls such as VUS interpretation and pseudodeficiency.

Key diagnostic concepts (with direct quotes)

• Screening: “thin-layer chromatography … useful screening test to find an abnormal urinary oligosaccharide pattern.” (khan2018sialidosisareview pages 3-5)
• Enzymology: “Deficiency of the lysosomal sialidase activity (neuraminidase) can be demonstrated in cultured skin fibroblasts …” (khan2018sialidosisareview pages 3-5)
• Differential from galactosialidosis: “β-galactosidase … should be normal” in sialidosis. (khan2018sialidosisareview pages 3-5)
• Confirmation: “The final diagnosis is made after whole genome sequencing.” (khan2018sialidosisareview pages 3-5)

Differential diagnosis (non-exhaustive)

• Galactosialidosis (CTSA/PPCA deficiency) with secondary NEU1 deficiency. (khan2018sialidosisareview pages 1-3)
• Other lysosomal storage diseases presenting with hepatosplenomegaly, dysostosis multiplex, or hydrops fetalis (general LSD diagnostic frameworks emphasize combined molecular + enzyme testing). (serrano2024hepatomegalyandsplenomegaly pages 7-8)

11. Outcome / prognosis

• Congenital/hydropic type II is often lethal: “Profoundly severe mutational alterations may lead to a complete absence of lysosomal neuraminidase and are lethal during fetal development or at birth.” (khan2018sialidosisareview pages 3-5)
• Severe type II is associated with multisystem morbidity and premature mortality; NIH natural-history protocol describes glycoproteinoses (including sialidosis) as “fatal or severely debilitating,” and states “No effective therapy … has yet been demonstrated.” (NCT00029965 chunk 1)

Robust survival curves, median survival, or subtype-stratified mortality statistics were not identified in the retrieved evidence.

12. Treatment

12.1 Current real-world management

No approved disease-modifying therapy is established; current care is primarily supportive. In the 2024 gene-therapy preprint: “Currently, there is no target treatment or cure available for type I or II sialidosis. Patients receive supportive care and symptomatic relief, primarily for the management of myoclonus and seizures.” (vlekkert2024aavmediatedgenetherapy pages 1-5)

12.2 Experimental and emerging therapeutics (preclinical emphasis)

Table: This table summarizes the current management landscape for sialidosis type II, from symptomatic care to preclinical gene therapy and enzyme/chaperone approaches. It also includes natural-history study infrastructure that is already being used in practice to support biomarker discovery and future interventional trials.

Key 2023–2024 development: dual AAV gene therapy (NEU1 + PPCA) in Neu1−/− mice. The abstract reports treated animals “phenotypically indistinguishable from their WT controls,” with “restoration of NEU1 activity in most tissues, reversal of sialyl-oligosacchariduria, and normalization of lysosomal exocytosis,” and prevention of generalized fibrosis. (vlekkert2024aavmediatedgenetherapy pages 1-5)

MAXO suggestions (high-level): antiseizure medication therapy; supportive care; genetic counseling; enzyme replacement therapy (experimental); gene therapy (AAV-based) (preclinical).

12.3 Clinical trials and real-world implementations

No interventional NEU1 gene therapy or ERT trials for sialidosis type II were identified in the retrieved trial list. However, natural history and biomarker studies relevant to future trials exist, including: - NCT00029965 (NIH): Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders (includes enzyme/DNA-confirmed sialidosis). (NCT00029965 chunk 1)

13. Prevention

Because this is a Mendelian autosomal recessive disorder, prevention focuses on recurrence-risk management: - Carrier detection and prenatal molecular diagnosis with genetic counseling are explicitly recommended in the congenital/type II context. (khan2018sialidosisareview pages 11-13)

Primary prevention via lifestyle or vaccination is not applicable.

14. Other species / natural disease

No naturally occurring (non-model) animal cases were identified in the retrieved evidence.

15. Model organisms and model systems

15.1 Mouse models (Neu1−/−)

Neu1−/− mice are widely used and closely resemble severe type II disease. The 2024 preprint states: “Neu1 knockout mice (Neu1−/−) closely resemble type II sialidosis … [with] severe growth retardation … premature death (4–6 months).” (vlekkert2024aavmediatedgenetherapy pages 1-5)

Kidney-specific mechanistic modeling of nephrosialidosis: Neu1-deficient mice show albuminuria, nephron loss, and renal fibrosis, and hypersialylation-driven megalin mistrafficking to lysosomes rather than the apical membrane. (kho2023severekidneydysfunction pages 1-2)

15.2 Cellular/iPSC models and technology applications

The NIH natural history protocol notes: “Some fibroblast lines will be used to create induced pluripotent stem cells (iPSC) for differentiation into neural tissues,” enabling CNS-relevant modeling and biomarker studies. (NCT00029965 chunk 1)

Evidence gaps and limitations of this report

1. Subtype-specific epidemiology (congenital/hydropic type II) and formal phenotype frequency distributions were not available from the retrieved sources; most numbers are for sialidosis overall. (kho2023severekidneydysfunction pages 1-2, mosca2020conventionalandunconventional pages 1-3)
2. Several clinical details for congenital cases are derived from aggregated historical case reports in reviews rather than contemporary multicenter registries. (khan2018sialidosisareview media 784849f6, khan2018sialidosisareview media 429fda1b, khan2018sialidosisareview media 29bee092)
3. Most disease-modifying therapy evidence remains preclinical (mouse models) and includes at least one preprint (bioRxiv), so clinical translation remains uncertain. (vlekkert2024aavmediatedgenetherapy pages 1-5, mosca2020conventionalandunconventional pages 1-3)

Key URLs (selected)

• OMIM Sialidosis (MIM 256550): https://omim.org/entry/256550 (cited via review) (khan2018sialidosisareview pages 3-5)
• Open Targets disease entity (MONDO_0009738, sialidosis type 2): https://platform.opentargets.org/disease/MONDO_0009738 (OpenTargets Search: Sialidosis)
• 2023 JCI Insight (kidney dysfunction in sialidosis mice): https://doi.org/10.1172/jci.insight.166470 (Published 2023-10-23) (kho2023severekidneydysfunction pages 1-2)
• 2024 bioRxiv preprint (AAV-mediated gene therapy for sialidosis): https://doi.org/10.1101/2023.11.10.566667 (Posted 2023-11-13; indexed 2024) (vlekkert2024aavmediatedgenetherapy pages 1-5)
• 2024 J Clin Med diagnostic approach to LSDs with hepatosplenomegaly: https://doi.org/10.3390/jcm13051465 (Published 2024-03) (serrano2024hepatomegalyandsplenomegaly pages 7-8)
• ClinicalTrials.gov natural history (NCT00029965): https://clinicaltrials.gov/study/NCT00029965 (First posted 2002-01-28; updated 2026-05-29) (NCT00029965 chunk 1)

References

1. (khan2018sialidosisareview pages 3-5): Aiza Khan and Consolato Sergi. Sialidosis: a review of morphology and molecular biology of a rare pediatric disorder. Diagnostics, 8:29, Apr 2018. URL: https://doi.org/10.3390/diagnostics8020029, doi:10.3390/diagnostics8020029. This article has 73 citations.

2. (vlekkert2024aavmediatedgenetherapy pages 1-5): Diantha van de Vlekkert, Huimin Hu, Leigh E. Fremuth, Scott A. Brown, Jason A. Weesner, Elida Gomero, Yvan Campos, and Alessandra d’Azzo. Aav-mediated gene therapy for sialidosis. bioRxiv, Nov 2024. URL: https://doi.org/10.1101/2023.11.10.566667, doi:10.1101/2023.11.10.566667. This article has 11 citations.

3. (kho2023severekidneydysfunction pages 1-2): Ikhui Kho, Ekaterina P. Demina, Xuefang Pan, Irene Londono, Christopher W. Cairo, Luisa Sturiale, Angelo Palmigiano, Angela Messina, Domenico Garozzo, Roth-Visal Ung, Fabrice Mac-Way, Éric Bonneil, Pierre Thibault, Mathieu Lemaire, Carlos R. Morales, and Alexey V. Pshezhetsky. Severe kidney dysfunction in sialidosis mice reveals an essential role for neuraminidase 1 in reabsorption. JCI Insight, Oct 2023. URL: https://doi.org/10.1172/jci.insight.166470, doi:10.1172/jci.insight.166470. This article has 14 citations and is from a domain leading peer-reviewed journal.

4. (khan2018sialidosisareview pages 1-3): Aiza Khan and Consolato Sergi. Sialidosis: a review of morphology and molecular biology of a rare pediatric disorder. Diagnostics, 8:29, Apr 2018. URL: https://doi.org/10.3390/diagnostics8020029, doi:10.3390/diagnostics8020029. This article has 73 citations.

5. (OpenTargets Search: Sialidosis): Open Targets Query (Sialidosis, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

6. (peng2025geneticinsightsand pages 1-2): Mei-Ling Peng, Siu-Fung Chau, Jia-Ying Chien, Peng-Yeong Woon, Yu-Chen Chen, Wai-Man Cheang, Hsien-Yang Tsai, and Shun-Ping Huang. Genetic insights and clinical implications of neu1 mutations in sialidosis. Genes, 16:151, Jan 2025. URL: https://doi.org/10.3390/genes16020151, doi:10.3390/genes16020151. This article has 10 citations.

7. (khan2018sialidosisareview media 784849f6): Aiza Khan and Consolato Sergi. Sialidosis: a review of morphology and molecular biology of a rare pediatric disorder. Diagnostics, 8:29, Apr 2018. URL: https://doi.org/10.3390/diagnostics8020029, doi:10.3390/diagnostics8020029. This article has 73 citations.

8. (khan2018sialidosisareview media 429fda1b): Aiza Khan and Consolato Sergi. Sialidosis: a review of morphology and molecular biology of a rare pediatric disorder. Diagnostics, 8:29, Apr 2018. URL: https://doi.org/10.3390/diagnostics8020029, doi:10.3390/diagnostics8020029. This article has 73 citations.

9. (khan2018sialidosisareview media 29bee092): Aiza Khan and Consolato Sergi. Sialidosis: a review of morphology and molecular biology of a rare pediatric disorder. Diagnostics, 8:29, Apr 2018. URL: https://doi.org/10.3390/diagnostics8020029, doi:10.3390/diagnostics8020029. This article has 73 citations.

10. (mosca2020conventionalandunconventional pages 1-3): Rosario Mosca, Diantha van de Vlekkert, Yvan Campos, Leigh E. Fremuth, Jaclyn Cadaoas, Vish Koppaka, Emil Kakkis, Cynthia Tifft, Camilo Toro, Simona Allievi, Cinzia Gellera, Laura Canafoglia, Gepke Visser, Ida Annunziata, and Alessandra d’Azzo. Conventional and unconventional therapeutic strategies for sialidosis type i. Journal of Clinical Medicine, 9:695, Mar 2020. URL: https://doi.org/10.3390/jcm9030695, doi:10.3390/jcm9030695. This article has 29 citations.

11. (khan2018sialidosisareview pages 11-13): Aiza Khan and Consolato Sergi. Sialidosis: a review of morphology and molecular biology of a rare pediatric disorder. Diagnostics, 8:29, Apr 2018. URL: https://doi.org/10.3390/diagnostics8020029, doi:10.3390/diagnostics8020029. This article has 73 citations.

12. (khan2018sialidosisareview pages 5-7): Aiza Khan and Consolato Sergi. Sialidosis: a review of morphology and molecular biology of a rare pediatric disorder. Diagnostics, 8:29, Apr 2018. URL: https://doi.org/10.3390/diagnostics8020029, doi:10.3390/diagnostics8020029. This article has 73 citations.

13. (peng2025geneticinsightsand pages 4-6): Mei-Ling Peng, Siu-Fung Chau, Jia-Ying Chien, Peng-Yeong Woon, Yu-Chen Chen, Wai-Man Cheang, Hsien-Yang Tsai, and Shun-Ping Huang. Genetic insights and clinical implications of neu1 mutations in sialidosis. Genes, 16:151, Jan 2025. URL: https://doi.org/10.3390/genes16020151, doi:10.3390/genes16020151. This article has 10 citations.

14. (kho2023severekidneydysfunction pages 9-11): Ikhui Kho, Ekaterina P. Demina, Xuefang Pan, Irene Londono, Christopher W. Cairo, Luisa Sturiale, Angelo Palmigiano, Angela Messina, Domenico Garozzo, Roth-Visal Ung, Fabrice Mac-Way, Éric Bonneil, Pierre Thibault, Mathieu Lemaire, Carlos R. Morales, and Alexey V. Pshezhetsky. Severe kidney dysfunction in sialidosis mice reveals an essential role for neuraminidase 1 in reabsorption. JCI Insight, Oct 2023. URL: https://doi.org/10.1172/jci.insight.166470, doi:10.1172/jci.insight.166470. This article has 14 citations and is from a domain leading peer-reviewed journal.

15. (peng2025geneticinsightsand pages 2-4): Mei-Ling Peng, Siu-Fung Chau, Jia-Ying Chien, Peng-Yeong Woon, Yu-Chen Chen, Wai-Man Cheang, Hsien-Yang Tsai, and Shun-Ping Huang. Genetic insights and clinical implications of neu1 mutations in sialidosis. Genes, 16:151, Jan 2025. URL: https://doi.org/10.3390/genes16020151, doi:10.3390/genes16020151. This article has 10 citations.

16. (khan2018sialidosisareview pages 13-14): Aiza Khan and Consolato Sergi. Sialidosis: a review of morphology and molecular biology of a rare pediatric disorder. Diagnostics, 8:29, Apr 2018. URL: https://doi.org/10.3390/diagnostics8020029, doi:10.3390/diagnostics8020029. This article has 73 citations.

17. (serrano2024hepatomegalyandsplenomegaly pages 7-8): Teodoro Jerves Serrano, Jessica Gold, James A. Cooper, Heather J. Church, Karen L. Tylee, Hoi Yee Wu, Sun Young Kim, and Karolina M. Stepien. Hepatomegaly and splenomegaly: an approach to the diagnosis of lysosomal storage diseases. Journal of Clinical Medicine, 13:1465, Mar 2024. URL: https://doi.org/10.3390/jcm13051465, doi:10.3390/jcm13051465. This article has 17 citations.

18. (peng2025geneticinsightsand pages 6-8): Mei-Ling Peng, Siu-Fung Chau, Jia-Ying Chien, Peng-Yeong Woon, Yu-Chen Chen, Wai-Man Cheang, Hsien-Yang Tsai, and Shun-Ping Huang. Genetic insights and clinical implications of neu1 mutations in sialidosis. Genes, 16:151, Jan 2025. URL: https://doi.org/10.3390/genes16020151, doi:10.3390/genes16020151. This article has 10 citations.

19. (serrano2024hepatomegalyandsplenomegaly pages 2-3): Teodoro Jerves Serrano, Jessica Gold, James A. Cooper, Heather J. Church, Karen L. Tylee, Hoi Yee Wu, Sun Young Kim, and Karolina M. Stepien. Hepatomegaly and splenomegaly: an approach to the diagnosis of lysosomal storage diseases. Journal of Clinical Medicine, 13:1465, Mar 2024. URL: https://doi.org/10.3390/jcm13051465, doi:10.3390/jcm13051465. This article has 17 citations.

20. (lange2024systematicdiagnosisof pages 4-6): Martin Lange, Nicoleta Corcodel, and Falk Schwendicke. Systematic diagnosis of lysosomal storage diseases in patients with hepatosplenomegaly. Bulletin of Pioneering Researches of Medical and Clinical Science, 4:66-80, Jan 2024. URL: https://doi.org/10.51847/isa3beaurx, doi:10.51847/isa3beaurx. This article has 0 citations.

21. (NCT00029965 chunk 1): Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders. National Human Genome Research Institute (NHGRI). 2002. ClinicalTrials.gov Identifier: NCT00029965

22. (khan2018sialidosisareview pages 14-16): Aiza Khan and Consolato Sergi. Sialidosis: a review of morphology and molecular biology of a rare pediatric disorder. Diagnostics, 8:29, Apr 2018. URL: https://doi.org/10.3390/diagnostics8020029, doi:10.3390/diagnostics8020029. This article has 73 citations.

23. (khan2022neu1—auniquetherapeutic pages 2-3): Aiza Khan and Consolato M. Sergi. Neu1—a unique therapeutic target for alzheimer’s disease. Frontiers in Pharmacology, Jun 2022. URL: https://doi.org/10.3389/fphar.2022.902259, doi:10.3389/fphar.2022.902259. This article has 20 citations.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02
• Edison artifact artifact-03